These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24966969)

  • 1. High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.
    Chen C; Li S; Lu X; Tan B; Huang C; Qin L
    Int J Clin Exp Pathol; 2014; 7(5):2558-64. PubMed ID: 24966969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231)].
    Cui GL; Ding H; Xu YJ; Chen C; Wang DW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jun; 40(6):477-81. PubMed ID: 22943641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
    Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
    Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform.
    Langaee T; Stauffer L; Galloway C; Solayman MH; Cavallari L
    Genet Test Mol Biomarkers; 2017 Apr; 21(4):259-264. PubMed ID: 28384046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
    Liu Y; Zhong SL; Yang M; Tan HH; Fei HW; Chen JY; Yu XY; Lin SG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Dec; 43(6):798-803. PubMed ID: 22178823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
    Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation.
    Huang TS; Zhang L; He Q; Li YB; Dai ZL; Zheng JR; Cheng PQ; He YS
    Australas Phys Eng Sci Med; 2017 Mar; 40(1):249-258. PubMed ID: 28083852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
    Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
    Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
    Langaee T; El Rouby N; Stauffer L; Galloway C; Cavallari LH
    Genet Test Mol Biomarkers; 2019 Mar; 23(3):209-214. PubMed ID: 30758238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement.
    Li J; Chen T; Jie F; Xiang H; Huang L; Jiang H; Lu F; Zhu S; Wu L; Tang Y
    Medicine (Baltimore); 2022 Jul; 101(29):e29626. PubMed ID: 35866816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
    Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
    Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.